|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500115814 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-31 14:10:08 |
|
注册时间: Date of Registration: |
2025-12-31 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
一种新型鼻牙槽塑形方式与传统鼻 牙槽塑形方式在单侧唇腭裂新生儿术前矫形治疗中的临床疗效对比——一项随机对照试验 |
|
Public title: |
Clinical efficacy of a novel kind of nasoalveolar molding appliance for nose-lip-alveolar shaping in infants with unilateral cleft lip and palate: a prospective trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
一种新型鼻牙槽塑形方式与传统鼻牙槽塑形方式在单侧唇腭裂新生儿术前矫形治疗中的临床疗效对比——一项随机对照试验 |
|
Scientific title: |
Comparison of the clinical efficacy of a new type of nasoalveolar shaping and traditional nasoalveolar shaping in the preoperative correction of unilateral cleft lip and palate neonates: a randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
郑洁 |
研究负责人: |
贺红 |
|
Applicant: |
Jie Zheng |
Study leader: |
Hong He |
|
申请注册联系人电话: Applicant telephone: |
+86 138 8602 2476 |
研究负责人电话:
Study leader's |
+86 189 7166 2305 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
sajonezj1989@whu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
drhehong@whu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国湖北省武汉市洪山区珞喻路237号 |
研究负责人通讯地址: |
中国湖北省武汉市洪山区珞喻路237号 |
|
Applicant address: |
No. 237, Luoyu Road, Hongshan District, Wuhan, Hubei, China |
Study leader's address: |
No. 237, Luoyu Road, Hongshan District, Wuhan, Hubei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
430079 |
研究负责人邮政编码: Study leader's postcode: |
430079 |
|
申请人所在单位: |
武汉大学口腔医院 |
||
|
Applicant's institution: |
Hospital of Stomatology, Wuhan University |
||
|
研究负责人所在单位: |
武汉大学口腔医院 |
||
|
Affiliation of the Leader: |
Hospital of Stomatology, Wuhan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[WDKQ2024]伦审字(D12)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
武汉大学口腔医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The Medical Ethics Committee of Wuhan University School of Stomatology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-07-08 00:00:00 | ||
|
伦理委员会联系人: |
丁洁 |
||
|
Contact Name of the ethic committee: |
Jie Ding |
||
|
伦理委员会联系地址: |
中国湖北省武汉市洪山区珞喻路237号 |
||
|
Contact Address of the ethic committee: |
No. 237, Luoyu Road, Hongshan District, Wuhan, Hubei, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 8768 6205 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
wdkqllwyh@163.com |
|
研究实施负责(组长)单位: |
武汉大学口腔医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hospital of Stomatology, Wuhan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国湖北省武汉市洪山区珞喻路237号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 237, Luoyu Road, Hongshan District, Wuhan, Hubei, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国际正畸基金会 |
||||||||||||||||||||||
|
Source(s) of funding: |
The International Orthodontics Foundation Limited |
||||||||||||||||||||||
|
研究疾病: |
唇腭裂 |
||||||||||||||||||||||
|
Target disease: |
Cleft Lip and Palate |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
对比经 3D 打印腭护板配合鼻钩构成的数字化鼻牙槽突塑形矫治器(Digital Presurgical Nasoalveolar Molding, DPNAM)矫治器治疗和经传统一体式鼻牙槽突塑形矫治器(Conventional Presurgical Nasoalveolar Molding, CPNAM )治疗后的单侧完全性唇腭裂患儿的上颌硬组织及鼻唇软组织的变化,比较两组患儿之间的变化差异,验证 DPNAM 矫治器在塑性鼻唇腭软硬组织方面是否优于或不差于CPNAM 矫治器,为单侧完全性唇腭裂患儿的鼻牙槽突裂术前矫形提供新的技术支持。同时,对患者家长进行半结构化访谈和标准化问卷,以评估治疗相关的社会心理健康和家庭影响 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study is to compare the changes in maxillary hard tissue and nasolabial soft tissue in children with unilateral complete cleft lip and palate after treatment with the Digital Presurgical Nasoalveolar Molding (DPNAM) appliance, which consists of a 3D-printed palatal plate combined with a nasal hook, and those treated with the Conventional Presurgical Nasoalveolar Molding (CPNAM) appliance. Analyze the differences in outcomes between the two groups to verify whether the DPNAM appliance is superior to or not inferior to the CPNAM appliance in shaping the nasolabial and palatal hard and soft tissues. This study aims to provide new technical support for presurgical nasoalveolar molding in children with unilateral complete cleft lip and palate. Additionally, conduct semi-structured interviews and standardized questionnaires with the parents of the patients to assess treatment-related psychosocial well-being and family impact. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.受试者家属在参与前提供书面知情同意书; 2.受试者在入组时是足月儿(出生孕周>37 周),且在出生后 30 天及以内; 3.受试者为非低体重儿(低体重<=2500g); 4.受试者诊断为非综合征型唇腭裂; 5.受试者为单侧完全性唇腭裂患者; 6.受试者完成了包括但不限于如下试验室检查:血常规,肝肾功能。且检查结果临床评价无异常; 7.受试者完成了包括但不限于如下影像学检查:胸片,心脏彩超。且检查结果临床评价无异常。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.The subject's family provides written informed consent prior to participation; 2.The subject is a full-term infant (gestational age at birth > 37 weeks) and within 30 days after birth at enrollment; 3.The subject is a non-low birth weight infant (low birth weight ≤ 2500g); 4.The subject is diagnosed with non-syndromic cleft lip and palate; 5.The subject has unilateral complete cleft lip and palate; 6.The subject has completed laboratory tests including but not limited to: complete blood count, liver and kidney function tests, with no clinically significant abnormalities in the test results; 7.The subject has completed imaging examinations including but not limited to: chest X-ray, echocardiogram, with no clinically significant abnormalities in the examination results. |
||||||||||||||||||||||
|
排除标准: |
1.受试者伴其他系统性疾病; 2.受试者出生缺氧; 3.受试者生长发育评估异常; 4.受试者家属拒绝在参与前提供书面知情同意书。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.The subject has other systemic diseases; 2.The subject experienced hypoxia at birth; 3.The subject has abnormal growth and development assessment results; 4.The subject's family members refuse to provide written informed consent prior to participation. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-08-01 00:00:00至 To 2027-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-08-19 00:00:00 至 To 2027-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
拟采用简单完全随机设计。首先将全部试验单元(40 个患儿)按照入组时间依次编为 1,2,…,40 号。然后采用随机数字表法将患者随机分配至试验组(20 例)和对照组(20 例)。患者随机分配由汪鑫医生负责,将通过序列编号的、密封的、不透光的信封进行随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A simple completely randomized design will be adopted. First, all trial units (40 pediatric patients) will be sequentially numbered 1, 2, …, 40 according to their enrollment time. Then, patients will be randomly assigned to the trial group (20 cases) and the control group (20 cases) using the random number table method. Dr. Wang Xin will be responsible for the random assignment of patients, which will be conducted using sequentially numbered, sealed, opaque envelopes. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
评价者盲 |
|
Blinding: |
Evaluators are blinded |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后6个月内,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Share via ResMan (www.medresman.org.cn) within 6 months of the clinical trial's completion. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |